Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

107.69 -1.11 (-1.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ascendis Pharma ADR

< Previous 1 2 3 4 5 Next >
7 Biotech Stocks With Key Catalysts in March
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. 
Via InvestorPlace
Expert Ratings For Ascendis Pharma
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
Via Benzinga
Pfizer Dives After FDA Rejects Its OPKO-Partnered Rare Disease Treatment
Pfizer stock tumbled after the FDA rejected an OPKO-partnered drug. 
Via Investor's Business Daily
Where Ascendis Pharma Stands With Analysts
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND 
Via Benzinga
Analyst Ratings For Ascendis Pharma
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND 
Via Benzinga
Earnings Scheduled For March 2, 2022
Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •... 
Via Benzinga
Where Ascendis Pharma Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval
The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH).... 
Via Benzinga
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,... 
Via Benzinga
Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
Ascendis Pharma A/S (NASDAQ: ASND) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP).... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
Upgrades For Canada Goose Holdings Inc (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Keybanc boosted the price target on Netflix, Inc. (NASDAQ: NFLX) from $690 to $725. Netflix shares rose 0.2% to $683.90 in pre-market trading. Piper Sandler raised the price... 
Via Benzinga
Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript
ASND earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
Upgrades For Iridium Communications Inc (NASDAQ:IRD... 
Via Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
Exposures Product Safety
Pfizer's Growth Hormone Candidate FDA Review Pushed By 3 Months
Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag. The FDA has pushed back... 
Via Benzinga
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In A Light Week
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and... 
Via Talk Markets
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and BioNTech SE (... 
Via Benzinga
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
Ascendis Pharma A/S (ASND) Q2 2021 Earnings Call Transcript
ASND earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Shares of Ascendis Soared This Week
The pharmaceutical company saw its shares jump more than $26. 
Via The Motley Fool
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers Support.com, Inc. (NASDAQ: SPRT) shares surged 41.1% to settle at $19.70 on Thursday on abnormally high volume. TSR, Inc. (NASDAQ: TSRI) shares rose 28.1% to close at $11... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.